"Productivity improvements have become a way of life."
– Bob Bradway, CEO of Amgen Inc., during the firm's second-quarter conference call

"The most damaging facet of SOX for the biotech industry has been the diversion of investment funds from science to compliance in the absence of product revenue."
– Jeff Hatfield, president and CEO of Vitae Pharmaceuticals Inc., from testimony at a hearing on the effect the regulatory burdens in Sarbanes-Oxley (SOX) have had on emerging biotech companies at the House Subcommittee on Capital Markets

"We'll need more innovation in the years ahead to finish the fight against AIDS."
– Jim Yong Kim, president of the World Bank